本文来源:时代财经时代财经从北海康成获悉,5月16日,北海康成对外宣布其全资子公司北海康成(上海)生物科技有限公司为持有人的注射用维拉苷酶β(商品名:戈芮宁)获国家药品监督管理局批准上市。戈芮宁是国内首个本土自主研发适用于12岁及以上青少年和成人I型和Ⅲ型戈谢病患者的长期酶替代治疗,属一类创新药并可替代同类进口产品,将大大提升国内患者用药可及。在商业化方面,北海康成对时代财经表示,这一药物的获批,...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.